FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations

Documenti analoghi

• FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
  di: Odogwu, Lauretta, et al.
  Pubblicazione: (2017)
• Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
  di: Čepulytė, Rūta, et al.
  Pubblicazione: (2020)
• Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
  di: Seo, Takuji, et al.
  Pubblicazione: (2020)
• Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
  di: Corcoran, Ryan B., et al.
  Pubblicazione: (2015)
• Dabrafenib and trametinib therapy in an elderly patient with non‐small cell lung cancer harboring the BRAF V600E mutation
  di: Dotsu, Yosuke, et al.
  Pubblicazione: (2020)